


Supplemental Figures


GPX3 supports ovarian cancer tumor progression *in vivo* and promotes expression of GDF15.

Chang *et al.*, 2024



Supplemental Figure 1. Effects of GPX3 knock-down on IP tumor burden in a syngeneic mouse ovarian cancer tumor model.

ID8 tumor cells transduced with pLK0.1 control, shGPX3-41 or shGPX3-39 shRNAs targeting GPX3 and cells injected IP into female C57BL/6J mice. GPX3 knock-down by shRNA-39 results in decreased peritoneal, diaphragm, GI and kidney tumors compared to control and shGPX3-41 transfected cells. Graphs show percentage of mice with indicated tumors (pLK0.1 control n=12, shGPX3-41 n= 8, shGPX3-39 n=6).



Supplemental Figure 2. Enrichment plots of gene expression signatures downregulated following GPX3 knock-down. OVCAR3 cells were stably transduced with two independent shRNAs against GPX3 (shGPX3-78 & -76) or scramble control. GSEA was carried out on differentially expressed genes identified by RNA sequencing following GPX3 knock-down. NES are shown in Figure 2B of the manuscript. Heatmaps of core leading-edge genes of each pathway are shown (z-scores).